Geron mit Hammernews!! - Älteste Beiträge zuerst (Seite 303)
eröffnet am 18.03.03 18:26:10 von
neuester Beitrag 21.03.24 13:47:21 von
neuester Beitrag 21.03.24 13:47:21 von
Beiträge: 3.090
ID: 709.348
ID: 709.348
Aufrufe heute: 2
Gesamt: 213.110
Gesamt: 213.110
Aktive User: 0
ISIN: US3741631036 · WKN: 902213 · Symbol: GON
3,5320
EUR
-2,02 %
-0,0730 EUR
Letzter Kurs 10.05.24 Tradegate
Neuigkeiten
02.05.24 · Business Wire (engl.)  |
25.04.24 · Business Wire (engl.) |
18.04.24 · Business Wire (engl.) |
03.04.24 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 8,2570 | +96,67 | |
| 17,440 | +44,61 | |
| 1,9750 | +27,42 | |
| 1,8400 | +26,03 | |
| 4,0000 | +25,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7275 | -18,72 | |
| 0,7100 | -19,32 | |
| 0,5350 | -20,15 | |
| 3,0800 | -23,76 | |
| 3,0740 | -77,41 |
Feedback
Interessant ist auch, daß immernoch 35 Mio. Aktien leerverkauft sind. Das ist immerhin fast jede sechste Aktie!
Falls hier Erfolgsmeldungen kommen, burn them Shorties 🔥
Falls hier Erfolgsmeldungen kommen, burn them Shorties 🔥
Hm, wer will denn da in STU & FRA zu jedem Preis rein?! 🧐
Wenn die 1,60$-Marke nachhaltig überwunden wird, dürfte es (charttechnisch) zügig Richtung 2$-Marke gehen...
wie ist eure Meinung und Prognose?
Trading Spotlight
Geron wird sicher die Unterstützung eines Großen benötigen um
weiter zu kommen.
Aber davon gehe ich aus sonst wäre ich nicht investiert.
Daher gehe ich von weiter steigenden Kursen aus.
weiter zu kommen.
Aber davon gehe ich aus sonst wäre ich nicht investiert.
Daher gehe ich von weiter steigenden Kursen aus.
2$-Marke in Reichweite...
Die hochdotierten Janssen Mitarbeiter kommen, die auch Imetelstat bei Janssen betreut haben, für mich ein Vertrauensbeweis, das wird:
Geron Expands Senior Leadership of Its Development Team
GlobeNewswire•April 18, 2019
MENLO PARK, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (GERN) today announced an expansion of its development team’s senior leadership with the addition of three highly experienced professionals for key functional areas. Their oncology and drug development expertise will support Geron’s late-stage clinical development, including the planned opening of the Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes for screening and enrollment by mid-year 2019.
Vice President, Clinical Development – Faye Feller, M.D.
Prior to Geron, Faye Feller, M.D., was Senior Director, Clinical Leader on the myeloid program at Janssen Research and Development, LLC (Janssen). Prior to that role, Dr. Feller was a physician for multiple clinical trials of late-stage development assets at Janssen, including the IMbark Phase 2 clinical trial of imetelstat, and was responsible for protocol writing, regulatory interactions, medical monitoring, study results interpretation and preparation of abstracts and final study reports. Prior to Janssen, Dr. Feller was an attending physician and instructor in the leukemia department of Memorial Sloan Kettering Cancer Center in New York. Dr. Feller holds a B.A. from New York University and an M.D. from Mount Sinai School of Medicine. She completed her residency in internal medicine at Mount Sinai Hospital and her fellowship in medical oncology at Memorial Sloan Kettering Cancer Center.
As Vice President, Clinical Development, Dr. Feller will provide hematology-oncology medical expertise to the clinical science and operations teams in the execution and monitoring of clinical trials. In addition, she will also act as the primary medical point of contact between Geron and other medically qualified healthcare professionals, including clinical investigators, prescribers, medical professionals at payer organizations and regulatory authorities.
Vice President, Clinical Science and Operations – Laurie Sherman
Laurie Sherman has more than 20 years of experience in oncology drug development. Prior to joining Geron, Ms. Sherman was Senior Director, Compound Development Team Leader for non-small cell lung cancer (NSCLC) assets at Janssen, where she was responsible for multiple aspects of drug development, including: clinical strategy and execution; chemistry, manufacturing and controls (CMC); toxicology; and clinical pharmacokinetics. Preceding that role, Ms. Sherman held several senior positions in the late-stage team at Janssen, including Senior Director, Myeloid Portfolio Clinical Scientist Leader, where she led development strategy and overall clinical execution of myeloid clinical trials, including the imetelstat clinical trials, IMerge and IMbark. Prior to that role she was Senior Director, Lead Project Scientist on the ibrutinib mantle cell lymphoma program. Ms. Sherman has held various positions with increasing responsibilities across various drugs’ product life cycles, from initial Phase 1 clinical trials through late-stage development, including operational leadership for pivotal Phase 3 clinical trials and supporting regulatory filings of New Drug Applications and Marketing Authorization Applications at multiple pharmaceutical companies and organizations, including: GlaxoSmithKline plc; Pfizer Inc.; World Wide Clinical Trials, Inc.; and Affiliated Research Institute. Ms. Sherman has a B.S. in nursing from the University of Washington.
As Vice President, Clinical Science and Operations, Ms. Sherman will provide oversight and management of current and future clinical trials, as well as strategic and technical guidance to and management of the Company’s contract research organization and other vendors supporting clinical operation activities. She will also directly oversee and manage internal operations and personnel involved with clinical operations, clinical science, data management and medical writing functions.
Vice President, Quality – Denise Grippo
Denise Grippo has more than 18 years of experience in drug development. Prior to joining Geron, Ms. Grippo was Vice President, Quality at Iovance Biotherapeutics, Inc. where she was responsible for developing and executing quality policies and plans to ensure lifecycle management of their early- and late-stage clinical oncology portfolio. In addition to Iovance, Ms. Grippo has held various quality and compliance positions with increasing responsibility and scope at XenoPort, Inc.; Mylan Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Alvogen, Inc.; and Marietta Corporation. Ms. Grippo has an M.S. in clinical chemistry from University of Scranton and a B.A. in biology from Temple University.
Geron Expands Senior Leadership of Its Development Team
GlobeNewswire•April 18, 2019
MENLO PARK, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (GERN) today announced an expansion of its development team’s senior leadership with the addition of three highly experienced professionals for key functional areas. Their oncology and drug development expertise will support Geron’s late-stage clinical development, including the planned opening of the Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes for screening and enrollment by mid-year 2019.
Vice President, Clinical Development – Faye Feller, M.D.
Prior to Geron, Faye Feller, M.D., was Senior Director, Clinical Leader on the myeloid program at Janssen Research and Development, LLC (Janssen). Prior to that role, Dr. Feller was a physician for multiple clinical trials of late-stage development assets at Janssen, including the IMbark Phase 2 clinical trial of imetelstat, and was responsible for protocol writing, regulatory interactions, medical monitoring, study results interpretation and preparation of abstracts and final study reports. Prior to Janssen, Dr. Feller was an attending physician and instructor in the leukemia department of Memorial Sloan Kettering Cancer Center in New York. Dr. Feller holds a B.A. from New York University and an M.D. from Mount Sinai School of Medicine. She completed her residency in internal medicine at Mount Sinai Hospital and her fellowship in medical oncology at Memorial Sloan Kettering Cancer Center.
As Vice President, Clinical Development, Dr. Feller will provide hematology-oncology medical expertise to the clinical science and operations teams in the execution and monitoring of clinical trials. In addition, she will also act as the primary medical point of contact between Geron and other medically qualified healthcare professionals, including clinical investigators, prescribers, medical professionals at payer organizations and regulatory authorities.
Vice President, Clinical Science and Operations – Laurie Sherman
Laurie Sherman has more than 20 years of experience in oncology drug development. Prior to joining Geron, Ms. Sherman was Senior Director, Compound Development Team Leader for non-small cell lung cancer (NSCLC) assets at Janssen, where she was responsible for multiple aspects of drug development, including: clinical strategy and execution; chemistry, manufacturing and controls (CMC); toxicology; and clinical pharmacokinetics. Preceding that role, Ms. Sherman held several senior positions in the late-stage team at Janssen, including Senior Director, Myeloid Portfolio Clinical Scientist Leader, where she led development strategy and overall clinical execution of myeloid clinical trials, including the imetelstat clinical trials, IMerge and IMbark. Prior to that role she was Senior Director, Lead Project Scientist on the ibrutinib mantle cell lymphoma program. Ms. Sherman has held various positions with increasing responsibilities across various drugs’ product life cycles, from initial Phase 1 clinical trials through late-stage development, including operational leadership for pivotal Phase 3 clinical trials and supporting regulatory filings of New Drug Applications and Marketing Authorization Applications at multiple pharmaceutical companies and organizations, including: GlaxoSmithKline plc; Pfizer Inc.; World Wide Clinical Trials, Inc.; and Affiliated Research Institute. Ms. Sherman has a B.S. in nursing from the University of Washington.
As Vice President, Clinical Science and Operations, Ms. Sherman will provide oversight and management of current and future clinical trials, as well as strategic and technical guidance to and management of the Company’s contract research organization and other vendors supporting clinical operation activities. She will also directly oversee and manage internal operations and personnel involved with clinical operations, clinical science, data management and medical writing functions.
Vice President, Quality – Denise Grippo
Denise Grippo has more than 18 years of experience in drug development. Prior to joining Geron, Ms. Grippo was Vice President, Quality at Iovance Biotherapeutics, Inc. where she was responsible for developing and executing quality policies and plans to ensure lifecycle management of their early- and late-stage clinical oncology portfolio. In addition to Iovance, Ms. Grippo has held various quality and compliance positions with increasing responsibility and scope at XenoPort, Inc.; Mylan Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Alvogen, Inc.; and Marietta Corporation. Ms. Grippo has an M.S. in clinical chemistry from University of Scranton and a B.A. in biology from Temple University.
Yep, sehr gutes Zeichen 👌
Eine Frage der Zeit, bis die 2$-Marke nachhaltig überwunden wird...und vor allem Shorties brennen zu sehen 🔥
Eine Frage der Zeit, bis die 2$-Marke nachhaltig überwunden wird...und vor allem Shorties brennen zu sehen 🔥
https://aleafiahealth.com/news-releases/aleafia-health-launc…
Ist dies die gleiche Technik die MK anbietet?
Ist dies die gleiche Technik die MK anbietet?
DurchsuchenBeitrag zu dieser Diskussion schreiben
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,87 | |
| -0,05 | |
| -1,79 | |
| -3,61 | |
| +2,14 | |
| -0,89 | |
| +0,07 | |
| +0,87 | |
| +0,90 | |
| 0,00 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 88 | ||
| 67 | ||
| 47 | ||
| 40 | ||
| 36 | ||
| 20 | ||
| 15 | ||
| 12 | ||
| 12 | ||
| 11 |
